A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease

PURPOSE: We evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of intravenous (IV) inclacumab, a fully human IgG4 anti–P-selectin monoclonal antibody in development for the treatment of sickle cell disease, at doses up to and exceeding those previously tested in h...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Christina Lourdes, Koeck, Kathleen, Hottmann, Margot, Redfern, Andrew, Davis, Mark, Barth, Aline, Geng, Xin, Hoppe, Carolyn, Yue, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427511/
https://www.ncbi.nlm.nih.gov/pubmed/37436495
http://dx.doi.org/10.1007/s00228-023-03514-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427511/
https://www.ncbi.nlm.nih.gov/pubmed/37436495
http://dx.doi.org/10.1007/s00228-023-03514-3

Ejemplares similares